On November 30, 2020 PureTech Health plc (LSE: PRTC, Nasdaq: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, reported that it will host its first R&D Day on Friday, December 11, 2020, beginning at 9:00 a.m., Eastern Time (Press release, PureTech Health, NOV 30, 2020, View Source [SID1234571991]). The virtual program will showcase PureTech’s scientific leadership in lymphatics and related immune pathways and share insights across its Wholly Owned Pipeline, which includes LYT-100, a clinical-stage anti-fibrotic and anti-inflammatory product candidate being advanced for the potential treatment of interstitial lung diseases and lymphedema, and LYT-200, a product candidate targeting foundational immunomodulatory mechanisms for the potential treatment of solid tumors.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
In addition to presentations by PureTech’s senior team, the R&D Day will feature talks from renowned scientists and physicians, including:
Toby Maher, M.D., professor of clinical medicine and director of interstitial lung disease at Keck School of Medicine of the University of Southern California
Siddhartha Mukherjee, M.D., DPhil, clinician and researcher at Columbia University and Pulitzer Prize-winning author of The Emperor of all Maladies and The Gene
Stanley Rockson, M.D., Allan and Tina Neill professor of lymphatic research and medicine at Stanford University; chief of consultative cardiology and director of the Stanford Center for Lymphatic and Venous Disorders
Zev Wainberg, M.D., co-director of the UCLA GI Oncology Program and assistant professor of medicine at UCLA
"PureTech’s inaugural R&D Day is an opportunity to bring together field-leading experts within our expansive global network to discuss the unique therapeutic opportunities within lymphatics and related immunology," said Daphne Zohar, chief executive officer of PureTech Health. "We have made great progress across our Wholly Owned Pipeline, which now includes four product candidates and three discovery platforms, and we look forward to detailing our differentiated approach towards addressing major diseases."
The agenda for PureTech’s R&D Day is:
Opening Remarks
Welcome from Chris Viehbacher, chairman of PureTech Board of Directors, and Bob Horvitz, Ph.D., chairman of PureTech R&D Committee
Perspectives from Daphne Zohar
Lymphatic Science Overview
The science underlying our Wholly Owned Pipeline, including the biology of the BIG Axis, lymphatic system and related immunology: Joe Bolen, Ph.D., chief scientific officer at PureTech
A clinical perspective on lymphatics and the need for innovation in lymphatic disorders and beyond: Stanley Rockson, M.D. (includes Q&A)
Fibrotic and Inflammatory Conditions – Unmet Need and LYT-100
Deep dive into LYT-100 and its potential to treat a range of conditions involving fibrosis, inflammation and impaired lymphatic flow: Michael Chen, Ph.D., head of innovation at PureTech
A pulmonology perspective on interstitial lung diseases, including IPF and Long COVID, and the unmet need: Toby Maher, M.D., Ph.D. (includes Q&A)
Remarks from Eric Elenko, Ph.D., chief innovation officer at PureTech
Immuno-Oncology – Prioritizing Targets and Future Directions
Perspectives on the field of immuno-oncology, where we are today and the clinical landscape: Siddhartha Mukherjee, M.D., DPhil, and Zev Wainberg, M.D.
Deep dive into LYT-200 and targeting galectin-9 for a range of cancer indications: Aleksandra Filipovic, M.D., Ph.D., head of oncology at PureTech
Fireside chat: What’s next? The future of immuno-oncology with Drs. Zev Wainberg and Siddhartha Mukherjee (includes Q&A)
Closing Remarks
PureTech’s vision for future growth and Q&A session with the PureTech senior management team
A webcast of the event will be available on the Investors section of PureTech’s website under Events & Presentations.